Table 3.
Summary performance of ID NOW (OPS vs. O + NS) compared with RT-PCR (OPS or NPS)
|
Oropharyngeal swab (OPS) for ID NOW testing | |||||
|---|---|---|---|---|---|
| Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | COVID-19 prevalence (%) | PPV (%) (95% CI) | NPV (%) (95% CI) | |
| Assessment centre: symptomatic | 92.5 (92.0–93.0) | 99.5 (99.4–99.5) | 15.0 | 96.9 (96.5–97.2) | 98.7 (98.6–98.8) |
| Assessment centre: asymptomatic | 84.6 (82.0–86.8) | 99.3 (99.1–99.4) | 8.4 | 91.3 (89.2–93.1) | 98.6 (98.3–98.8) |
| Hospital | 89.5 (88.3–90.6) | 99.3 (99.2–99.4) | 17.3 | 96.4 (95.7–97.1) | 97.8 (97.6–98.0) |
| Mobile: symptomatic | 88.0 (85.2–90.5) | 99.4 (99.1–99.6) | 14.2 | 96.0 (94.1–97.3) | 98.0 (97.6–98.4) |
| Mobile: asymptomatic | 73.9 (69.8–77.7) | 99.6 (99.5–99.7) | 2.5 | 82.4 (78.8–85.5) | 99.3 (98.8–99.1) |
| Emergency shelters and addiction treatment facilities | 76.5 (65.8–85.3) | 99.6 (99.2–99.8) | 4.2 | 88.6 (79.3–94.0) | 99.0 (98.5–99.3) |
| Combined oropharyngeal and nasal swab (O+NS) for ID NOW testing | |||||
| Sensitivity (%) (95% CI) | Specificity (%) (95% CI) | COVID-19 prevalence (%) | PPV (%) (95% CI) | NPV (%) (95% CI) | |
| Assessment centre: symptomatic | 92.3 (89.0–94.8) | 99.5 (99.2–99.7) | 9.3 | 94.9 (92.1–96.7) | 99.2 (98.9–99.4) |
| Assessment centre: asymptomatic | 77.8 (62.9–88.8) | 99.2 (98.2–99.7) | 6.6 | 87.5 (74.3–94.4) | 98.4 (97.3–99.1) |
| Emergency shelters and addiction treatment facilities | 75.0 (19.4–99.4) | 100 (98.1–100) | 2.1 | 100 | 99.5 (97.2–99.9) |
COVID-19, coronavirus disease 2019; NPS, nasopharyngeal swab; NPV, negative predictive value; O + NS, combined oropharyngeal + nasal swab; OPS, oropharyngeal swab; PPV, positive predictive value.